Article
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2011
Faratian Dana, Zweemer Annelien J M, Nagumo Yoko, Sims Andrew H, Muir Morwenna, Dodds Michael, Mullen Peter, Um Inhwa, Kay Charlene, Hasmann Max, Harrison David J, Langdon Simon P
Abstract excerpt
PURPOSE: The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated. EXPERIMENTAL DESIGN: The effects of trastuzumab, pertuzumab, and letrozole on growth response, apoptosis, morphology, and gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.